1. Scrip

A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation

 
• By Edwin Elmhirst

An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.

Taking a look at commercial performance of the 10 drugs selected for the initial round of Medicare price negotiation underscores that while they are mega-blockbuster products and large contributors to overall Medicare spending, they are largely mature products approaching the end of their commercial lifecycles.

The drugs chosen for negotiation are, by the nature of the selection criteria, large revenue generators for the companies that market them

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.